Abstract
14P Consolidative stereotactic radiotherapy in metastatic EGFR-mutant non-small cell lung cancer receiving first-line third-generation EGFR tyrosine kinase inhibitors: A prospective, multicenter, phase II trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have